Longitude Capital Partners IV, LLC
Longitude Capital Partners IV, LLC's purchase track record
How the stock did after each of Longitude Capital Partners IV, LLC's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/7/2023 | LXEO | $5.00M | +55.7% | +28.4% | +18.5% |
| 2/6/2023 | VERA | $12.00M | +8.5% | +158.3% | +9.9% |
| 2/10/2022 | VERA | $5.00M | -18.5% | +8.7% | -6.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Leerink Partners Covers Vera Therapeutics at $34 Target. Leerink Partners has started coverage of Vera Therapeutics, giving it a Market Perform rating and a price target of $34. The target sits near the lower end of the company’s 52‑week range and close to the current support level of $33.79. The new rating may influence how traders view the stock’s short‑term prospects. The RSI of 37 suggests the stock is not overbought or oversold at this time.
Transaction History
| LXEO | ▲ Buy | Open Market | 454,545 | $5.0M | 11/7/2023 | View on chart |
| LXEO | ▼ Sell | Other | 319,126 | — | 11/7/2023 | View on chart |
| LXEO | ▼ Sell | Other | 1,793,429 | — | 11/7/2023 | View on chart |
| VERA | ▲ Buy | Open Market | 1,714,285 | $12.0M | 2/6/2023 | View on chart |
| VERA | ▲ Buy | Open Market | 333,333 | $5.0M | 2/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
LXEO to Acquire Mantle Therapeutics, Expand Friedreich Ataxia Programs
Lexeo Therapeutics announced an agreement to acquire Mantle Therapeutics and enter new collaborations to expand its Friedreich Ataxia portfolio. The company also secured access to Apertura’s TfR1 CapX technology for its treatment programs. These strategic moves aim to strengthen Lexeo's position in the rare disease space, though the stock remains in a technical downtrend.
LXEO to Acquire Mantle Therapeutics, Expand Friedreich Ataxia Programs. Lexeo Therapeutics announced an agreement to acquire Mantle Therapeutics and enter new collaborations to expand its Friedreich Ataxia portfolio. The company also secured access to Apertura’s TfR1 CapX technology for its treatment programs. These strategic moves aim to strengthen Lexeo's position in the rare disease space, though the stock remains in a technical downtrend.